NDAINJECTIONINJECTABLEPriority Review
Approved
Aug 1952
Lifecycle
LOE Approaching
Competitive Pressure
45/100
Data completeness
4/8 — Partial
Priority Review
ANECTINE (succinylcholine chloride) by Novartis is blocker. Approved for mechanical ventilation. First approved in 1952.
Drug data last refreshed 5h ago · AI intelligence enriched 5d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
ANECTINE (succinylcholine chloride) is a depolarizing neuromuscular blocking agent approved in 1952 for rapid-onset skeletal muscle paralysis during mechanical ventilation and anesthesia. It works by mimicking acetylcholine at the motor end plate, causing initial fasciculations followed by sustained depolarization that blocks neuromuscular transmission for 4–6 minutes. The drug enables intubation and surgical access in acute care settings.
LOE Approaching
Product approaching loss of exclusivity with moderate competitive pressure (45/100), signaling potential team downsizing or transition to generic optimization and cost management roles.
Mechanism of Action
blocker. As does acetylcholine, it combines with the cholinergic receptors of the motor end plate to produce depolarization. This depolarization may be observed as fasciculations. Subsequent neuromuscular transmission is inhibited so long as adequate concentration of succinylcholine remains at the…
Indications (1)
Worked on ANECTINE at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.